PARD - Poniard Pharmaceuticals, Inc. (NASDAQ Stock)

[greencat]

Watching for a breakout.






Poniard Pharmaceuticals, Inc.
7000 Shoreline Court
Suite 270
South San Francisco, CA 94080
United States - Map
Phone: 650-583-3774
Fax: 650-583-3789
Web Site: Poniard

DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 59


BUSINESS SUMMARY
Poniard Pharmaceuticals, Inc., together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of oncology products for people with cancer. Its lead platform product candidate, Picoplatin, is a platinum-based cancer therapy that is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Picoplatin is being studied in various cancer indications, combinations, and formulations. Poniard Pharmaceuticals is conducting a phase III clinical trial of intravenous picoplatin in small cell lung cancer; two phase II clinical trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers; and a clinical trial of oral picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in June 2006. Poniard Pharmaceuticals was founded in 1984 and is headquartered in South San Francisco, California.

[BadThad]

Down to $2.14, looks like the bottom is forming.

[Aufan 1983]

Big news out over the weekend. Looks like they met phase 2 objectives. Could be a nice multi day runner.

I bought in Friday @ 2.53 so fingers are crossed.

[greencat]

PARD has a nice candle setup and it may try to break the trendline and make a higher high.

PARD Chart

[greencat]

PARD broke a small term trendline giving a buy signa'. PARD is also in a bullish inverted head and shoulders pattern. I expect PARD to make a nice move.

PARD Chart

[greencat]

PARD taking off

Originally Posted by greencat

PARD broke a small term trendline giving a buy signa'. PARD is also in a bullish inverted head and shoulders pattern. I expect PARD to make a nice move.

PARD Chart